金龙胶囊联合西医疗法治疗原发性肝癌效果的Meta分析

时克; 王晓静; 王宪波

doi:10.3969/j.issn.1001-5256.2019.11.021

金龙胶囊联合西医疗法治疗原发性肝癌效果的Meta分析

DOI: 10.3969/j.issn.1001-5256.2019.11.021

1. 北京中医药大学东直门医院
2. 首都医科大学附属北京地坛医院中西医结合中心

基金项目:

北京市医院管理局临床医学发展专项经费资助(ZYLX201707)；国家中医药管理局重大疑难疾病中西医临床协作试点项目(2018-6-4);国家中医药管理局区域中医(肝病)诊疗中心(2019-3-18)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1246
- HTML全文浏览量: 34
- PDF下载量: 263
- 被引次数: 0
出版历程
- 收稿日期: 2019-06-24
- 出版日期: 2019-11-20

Clinical effect of Jinlong capsules combined with Western medicine treatment in treatment of primary liver cancer:A Meta-analysis

Dongzhimen Hospital,Beijing University of Chinese Medicine

Research funding:

摘要

摘要: 目的探讨金龙胶囊联合西医疗法治疗中晚期原发性肝癌的疗效及不良反应。方法通过计算机检索PubMed、The Cochrane Library、中国知网、万方数据库、中国生物医学文献数据库、维普中文科技期刊数据库2019年5月之前的文献,全面收集金龙胶囊联合西医疗法治疗原发性肝癌的随机对照试验,干预组为金龙胶囊联合西医治疗,对照组为单纯西医治疗。对纳入的文献提取资料及质量评价,通过RevMan 5. 3软件,采用固定或随机效应模型进行Meta分析。结果纳入26篇文献,共2318例患者,干预组1175例,对照组1143例。分析结果显示,金龙胶囊联合西医疗法与单纯西医疗法相比,能提高有效率[相对危险度（RR）=1. 36,95%可信区间（95%CI）:1. 25～1. 49,P <0. 001]、1年生存率（RR=1. 29,95%CI:1. 14～1. 47,P <0. 001）、KPS评分（RR=1. 37,95%CI:1. 19～1. 59,P <0. 001）和外周血CD3+T淋巴细胞[均数差（MD）=11. 18,95%CI:2. 68～19....
- 肝肿瘤 /
- 金龙胶囊 /
- 中西医结合 /
- 治疗结果 /
- Meta分析
Abstract: Objective To investigate the clinical effect and adverse events of Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer. Methods PubMed,The Cochrane library,CNKI,Wanfang Data,CBM,and VIP were searched for randomized controlled trials( RCTs) on Jinlong capsules combined with Western medicine treatment in the treatment of advanced primary liver cancer published up to May 2019. The patients treated with Jinlong capsules combined with Western medicine treatment were enrolled as intervention group,and those treated with Western medicine treatment alone were enrolled as control group. Data extraction and quality assessment were performed,and RevMan 5. 3 was used to perform the Meta-analysis with a fixed or random effects model.Results A total of 26 RCTs were included,with a total of 2318 patients( 1175 patients in the intervention group and 1143 patients in the control group). The results of the Meta-analysis showed that compared with Western medicine treatment alone,Jinlong capsules combined with Western medicine treatment had significant increases in response rate( relative risk [RR] = 1. 36,95% confidence interval [CI]:1. 25-1. 49,P < 0. 001),1-year survival rate( RR = 1. 29,95% CI: 1. 14-1. 47,P < 0. 001),Karnofsky Performance Scale score( RR = 1. 37,95% CI: 1. 19-1. 59,P < 0. 001),peripheral blood CD3+T lymphocytes( mean difference [MD]= 11. 18,95% CI: 2. 68-19. 68,P = 0. 01),CD4+T lymphocytes( MD = 6. 43,95% CI: 3. 82-9. 05,P < 0. 001),and CD4+/CD8+ratio( MD = 0. 31,95% CI: 0. 26-0. 36,P < 0. 001),as well as significant reductions in rate of progression( RR = 0. 41,95% CI: 0. 29-0. 57,P < 0. 001),rate of leucopenia( RR = 0. 65,95% CI: 0. 57-0. 75,P < 0. 001),incidence rate of gastrointestinal reactions( RR = 0. 72,95% CI: 0. 59-0. 88,P= 0. 001),and peripheral blood CD8+T lymphocytes( MD =-4. 68,95% CI:-5. 84 to-3. 51,P < 0. 001). Conclusion Jinlong capsules combined with Western medicine treatment has a marked clinical effect in the treatment of advanced primary liver cancer with few adverse events and thus holds promise for clinical application.
- liver neoplasms /
- Jinlong capsules /
- integrated TCM WM /
- treatment outcome /
- Meta-analysis

HTML全文

参考文献(39)

[1] National Health and Family Planning Commission of the People’s Republic of China. Diagnosis,management,and treatment of hepatocellular carcinoma(V2017)[J]. J Clin Hepatol,2017,33(8):1419-1431.(in Chinese)中华人民共和国国家卫生和计划生育委员会．原发性肝癌诊疗规范(2017年版)[J]．临床肝胆病杂志，2017,33(8):1419-1431.

[2] WANG FS,FAN JG,ZHANG Z,et al. The global burden of liver disease:The major impact of China[J]. Hepatology,2014,60(6):2099-2108.

[3] JIANG MN,LI XY,LI JR,et al. Impact of individual diet intervention on nutritional status and quality of life of senile patients with hepatocellular carcinoma after TACE operation[J]. J Changchun Univ Chin Med,2019,35(1):150-152.(in Chinese)江美娜，李修瑛，李佳睿，等．个体化饮食营养干预对老年肝癌患者肝动脉化疗栓塞术后营养状况及生活质量的影响[J]．长春中医药大学学报，2019,35(1):150-152.

[4] SHI J,ZHANG W,HE L,et al. Jinlong capsule inhibits migration and invasion in human glioblastoma cells via the modulation of m TOR/S6 signaling pathway[J]. Drug Des Devel Ther,2019,1(13):1023-1032.

[5] LU Q,LUO JB,FENG YF,et al. Jinlong capsule combined withchemoradiotherapy for NSCLC:A meta-analysis[J].China J Chin Mater Med,2015,40(22):4491-4496.

[6] HUANG H,CUI XW,YUE GJ,et al. Inhibitory effect of jinlong capsules on gliomatosis cerebri and mechanisms[J]. Pharm J Chin PLA,2014,30(3):188-191.

[7] LI D,LIU YQ. Research progress of Jinlong capsule in antitumor[J]. Hubei J Tradit Chin Med,2018,40(8):57-60.(in Chinese)李丹，刘延庆．金龙胶囊抗肿瘤的研究进展[J]．湖北中医杂志，2018,40(8):57-60.

[8] LIU YQ,GAO J,LI JS. The effcts and the mechenism of fresh TCM recipe on tumor recurrence and metastasis[J]. Beijing Med J,2005,27(9):554-557.(in Chinese)刘玉琴，高进，李建生．金龙胶囊抗肿瘤复发、转移的实验研究[J]．北京医学，2005,27(9):554-557.

[9] ZHENG C,ZHANG RS,PAN Y. Effects of Jinlong capsule and interventional therapy on primary hepatocellular carcinoma and T lymphocyte subsets and tumor immune factor[J]. Mod Digest Interv,2018,23(4):506-509.(in Chinese)郑操，张荣胜，潘勇．金龙胶囊与介入治疗原发性肝癌的疗效及对T淋巴细胞亚群、肿瘤免疫因子的影响[J]．现代消化及介入诊疗，2018,23(4):506-509.

[10] MENG P. Clinical efficacy and mechanism of Jinlong capsule plus hepatic artery embolism for primary liver cancer[J].Pract J Cancer,2016,31(3):403-406.(in Chinese)孟平．金龙胶囊配合肝动脉化疗栓塞术治疗原发性肝癌的疗效及机制分析[J]．实用癌症杂志，2016,31(3):403-406.

[11] LIU ZY,ZHANG HH,ZHANG XS,et al. Therapeutic effect of Jinlong capsule combined with TACE on primary hepatocellular carcinoma[J]. Heilongjiang Med Pharm,2015,38(4):75-76.(in Chinese)刘振玉，张烜赫，张雪松，等．金龙胶囊联合TACE治疗原发性肝癌疗效观察[J]．黑龙江医药科学，2015,38(4):75-76.

[12] ZENG CS,CAI LM,LI JW,et al. Influence of jinlong capsule combined with transarterial chemo-embolization on quality of life of patients with primary liver cancer[J]. Chin J Clin Oncol,2012,39(22):1839-1842.(in Chinese)曾春生，蔡联明，李金伟，等．金龙胶囊对原发性肝癌患者介入治疗后生存质量的影响[J]．中国肿瘤临床，2012,39(22):1839-1842.

[13] JIANG CY,CAO JJ,CHENG Q. Clinical evaluation of Jinlong capsule combined with TACE in the treatment of primary hepatocellular carcinoma[J]. Med Innov Chin,2013,10(26):110-111.(in Chinese)蒋潮涌，曹晶杰，程琼．金龙胶囊联合TACE治疗原发性肝癌的临床评价[J]．中国医学创新，2013,10(26):110-111.

[14] LI B,ZHAO LX,LIU ZW,et al. Jinlong capsule combined with interventional therapy for primary hepatocellular carcinomas:A clinical analysis on 150 patients[J]. Chin J Hepatobiliary Surg,2013,19(7):530-533.(in Chinese)李宾，赵立新，刘志伟，等．金龙胶囊联合介入治疗原发性肝癌150例临床分析[J]．中华肝胆外科杂志，2013,19(7):530-533.

[15] YANG PY,SUN YY,ZHANG YC,et al. Effectiveness of early intervention with Jin-long capsules and transarterial chemoembolization for the treatment of primary liver cancer[J]. Chin J Clin Oncol,2013,40(1):45-49.(in Chinese)杨佩颖，孙一予，张蕴超，等．金龙胶囊先期干预TACE治疗原发性肝癌的临床研究[J]．中国肿瘤临床，2013,40(1):45-49.

[16] ZHANG XQ,GUO P,DANG ZJ,et al. Kinglong capsules combined with interventional therapy forhepatocellular carcinomas:clinical observation[J]. J Interventronal Radiol,2012,21(3):249-251.(in Chinese)张晓前，郭鹏，党之俊，等．金龙胶囊联合介入疗法治疗原发性肝癌临床观察[J]．介入放射学杂志，2012,21(3):249-251.

[17] ZENG BZ,YANG YQ,HAN XW. Effect of Jinlong capsule combined with TACE in treatment of 31 cases of primary hepatocellular carcinoma[J]. Tradit Chin Med Res,2010,23(8):35-37.(in Chinese)曾宝珠，杨亚琴，韩新巍．金龙胶囊联合TACE治疗原发性肝癌31例[J]．中医研究，2010,23(8):35-37.

[18] WU GL,ZHANG L,LI TY,et al. Short-term effect of combined therapy with jinlong capsule and transcatheter arterial chemoembolization on patients with primary hepatic carcinoma and its influence on serum osteopontin expression[J]. Chin J Integr Med,2010,16(2):109-113.

[19] WEN SW,DANG ZJ,YUAN TW. Clinical evaluation of Jinlong capsule on improving quality of life of patients with hepatocellular carcinoma after interventional therapy[J]. Capit Med,2010,17(16):55.(in Chinese)温树伟，党之俊，苑天文．金龙胶囊改善肝癌介入患者生存质量的临床评价[J]．首都医药，2010,17(16):55.

[20] DONG HT,ZHAO W,LU WP,et al. Clinical observation on133 cases of primary hepatocellular carcinoma treated by Jinlong capsule and hepatic artery intervention[J]. Chin J Clin Oncol,2008,35(7):378-380.(in Chinese)董海涛，赵炜，卢雯平，等．金龙胶囊并肝动脉介入治疗原发性肝癌133例临床观察[J]．中国肿瘤临床，2008,35(7):378-380.

[21] JIA CH,WANG WY,KANG Y,et al. Clinical studies on combination therapy of jinlong capsule and transarterial chemoembolization intreatment of primary hepatic carcinoma[J]. Chin J Cancer Prev Treat,2008,15(18):1416-1418.(in Chinese)贾长河，王文玉，康谊，等．金龙胶囊配合肝动脉灌注化疗栓塞治疗肝癌的临床研究[J]．中华肿瘤防治杂志，2008,15(18):1416-1418.

[22] XIE YF,TAN XF,MA QH,et al. Clinical observation of Jinlong capsule combined with interventional therapy in the treatment of hepatocellular carcinoma[J]. Chin J Clin Oncol,2003,30(4):73-74.(in Chinese)谢印法，谭学芬，马青华，等．金龙胶囊联合介入治疗肝癌临床观察[J]．中国肿瘤临床，2003,30(4):73-74.

[23] ZHANG CQ,LIANG TJ,YUAN MB. Clinical studies of the combination therapy with jinlong capsule and chemical therapy and embolization by hepatic artery catheterization on primary hepatic carcinoma[J]. Beijing Med J,2005,27(6):357-359.(in Chinese)张才擎，梁铁军，袁孟彪．金龙胶囊联合肝动脉化疗栓塞治疗原发性肝癌疗效观察[J]．北京医学，2005,27(6):357-359.

[24] SUN JH,YANG SS,MA YL. Effect of Jinlong capsule on quality of life and survival period of advanced hepatocellular carcinoma[J]. Hubei J Tradit Chin Med,2006,28(5):34.(in Chinese)孙建海，杨水生，马燕凌．金龙胶囊对晚期肝癌生存质量及生存期的影响[J]．湖北中医杂志，2006,28(5):34.

[25] ZHU X. Clinical observation of Jinlong capsule in the treatment of advanced primary hepatocellular carcinoma[J]. Mod J Integr Tradit Chin West Med,2003,12(16):1739-1740.(in Chinese)朱霞．金龙胶囊治疗晚期原发性肝癌的疗效观察[J]．现代中西医结合杂志，2003,12(16):1739-1740.

[26] XIONG TQ,WANG QF,ZHANG Y. Analysis of 26 cases of primary liver cancer treated with Jinlong capsule[J]. J Med Theor Pract,2010,23(1):51-52.(in Chinese)熊天琴，王琼芬，张愚．金龙胶囊治疗原发性肝癌26例分析[J]．医学理论与实践，2010,23(1):51-52.

[27] ZHANG SZ,YANG MD,GAO J. Clinical analysis of Jinlong capsule in the treatment of 22 cases of primary liver cancer[J]. Capit Med,2012,19(20):35-36.(in Chinese)张素珍，杨牡丹，高峻．金龙胶囊治疗原发性肝癌22例临床分析[J]．首都医药，2012,19(20):35-36.

[28] WANG HB,YANG JQ. Combination therapy of jinlong capsule and three-dimensional conformal radiotherapy for primary hepatocellular carcinoma[J]. Chin J Clin Oncol,2013,40(13):784-787.(in Chinese)汪宏斌，杨俊泉．金龙胶囊联合三维适形放疗治疗原发性肝癌[J]．中国肿瘤临床，2013,40(13):784-787.

[29] YIN LJ,ZHAO GH,DING TG. Effect of Jinlong capsule combined with whole body gamma knife in the treatment of 96 cases of primary hepatocellular carcinoma[J]. Chin J Clin Oncol,2008,35(7):381-382.(in Chinese)尹立杰，赵国华，丁田贵．金龙胶囊联合全身伽玛刀治疗原发性肝癌96例[J]．中国肿瘤临床，2008,35(7):381-382.

[30] XIAO ZY,DENG JH,XIONG SZ,et al. Therapeutic effect of three-dimensional conformal radiotherapy combined with Jinlong capsule on 52 cases of primary hepatocellular carcinoma[J]. Capit Med,2009,16(16):45-46.(in Chinese)肖震宇，邓江华，熊士忠，等．三维适形放疗联合金龙胶囊治疗原发性肝癌52例疗效分析[J]．首都医药，2009,16(16):45-46.

[31] LIU XT,LIU JB,ZHANG ZQ,et al. Clinical observation of Jinlong capsule combined with radiofrequency ablation in the treatment of primary liver cancer[J]. Capit Med,2013,10:47-48.(in Chinese)．刘溪涛，刘俊斌，张志芹，等．金龙胶囊联合射频消融技术对治疗原发性肝癌的临床观察[J]．首都医药，2013,10:47-48.

[32] YE X,GE ZM,FEI XB,et al. Clinical study on HIFU combined with jinlong capsules in treating 54 cases of primary liver cancer[J]. Chin J Clin Oncol,2008,35(7):372-374.(in Chinese)叶欣，葛忠民，费兴波，等．高强度聚焦超声联合金龙胶囊治疗原发性肝癌54例疗效分析[J]．中国肿瘤临床，2008,35(7):372-374.

[33] FAN XW,HUANG WK,YANG SF. Clinical observation of radiofrequency ablation combined with Jinlong capsule in the treatment of primary hepatocellular carcinoma[J]. Capit Food Med,2015,22(12):57-59.(in Chinese)樊喜文，黄伍奎，杨树法．射频消融联合金龙胶囊治疗原发性肝癌的临床疗效观察[J]．首都食品与医药，2015,22(12):57-59.

[34] LU ZY,CAI LM,LIU ZH,et al. Effects of jinlong capsule on immune index of the microwave ablation inthe treatment of hepatocellular carcinoma[J]. J Gannan Med Coll,2015,35(4):590-592.(in Chinese)卢致洋，蔡联明，刘振华，等．肝癌微波消融治疗后金龙胶囊对免疫指标(CD系列)影响及临床研究[J]．赣南医学院学报，2015,35(4):590-592.

[35] LI Y,TIAN JB. Effect of jinglong capsule combined with docetaxel,epirubicin,cyclophosphamide(TEC)in new adjuvant chemotherapy of gastric cancer[J]. J Liaoning Univ Tradit Chin Med,2017,19(9):193-194.(in Chinese)李雨，田静彬．金龙胶囊联合多西他赛表柔比星环磷酰胺方案在胃癌新辅助化疗中应用效果[J]．辽宁中医药大学学报，2017,19(9):193-194.

[36] DING XL,MAN YN,HAO J,et al. The antitumor effect of gekko sulfated glycopeptide by inhibiting bFGF-induced iymphangiogenesis[J]. Biomed Res Int,2016,2016:7396392.

[37] HUANG H,CUI XW,YUE GJ,et al. Inhibitory effect of Jinlong capsules on gliomatosis cerebri and mechanisms[J]. Pharm J Chin PLA,2014,30(3):188-191.(in Chinese)黄卉，崔向微，岳贵娟，等．复方中药金龙胶囊抗脑肿瘤药效及机制的初步探讨[J]．解放军药学学报，2014,30(3):188-191.

[38] LI YY,HU JQ,HUANG H,et al. Effect of jinlong capsule on proliferation and apoptosis of human pancreatic cancer cellsBxPC-3[J]. J Tradit Chin Med,2013,33(2):205-210.

[39] LIU JP,YUAN CJ,YU T,et al. Effect of jinlong capsule on vasculogenic mimicry and Mig-7 of colon cancer[J]. Cancer Res Prev Treat,2016,43(12):1059-1062.(in Chinese)刘娇萍，袁昌劲，余涛，等．金龙胶囊对结肠癌血管生成拟态及Mig-7的影响[J]．肿瘤防治研究，2016,43(12):1059-1062.

施引文献

资源附件(0)

访问统计